Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 8/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30006081 | 1.00 | MOGAT2 (0.40) | MOGAT2AKR1B1NR3C1PGRNR3C2 | |
| SCHEMBL30668452 | 0.83 | MOGAT2 (0.39) | MOGAT2NR3C1PGRNR3C2AR | |
| SCHEMBL21624342 | 0.83 | MOGAT2 (0.39) | MOGAT2NR3C1PGRNR3C2AR | |
| SCHEMBL21624389 | 0.83 | MOGAT2 (0.36) | MOGAT2NR3C1PGRKMT2A | |
| SCHEMBL21624325 | 0.79 | — | — | |
| SCHEMBL30668453 | 0.79 | — | — | |
| SCHEMBL30668483 | 0.79 | MOGAT2 (0.43) | MOGAT2AKR1B1AR | |
| SCHEMBL21624379 | 0.79 | MOGAT2 (0.38) | MOGAT2AKR1B1 | |
| SCHEMBL21624366 | 0.79 | MOGAT2 (0.43) | MOGAT2AKR1B1AR | |
| SCHEMBL30668486 | 0.79 | MOGAT2 (0.38) | MOGAT2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | GRUENENTHAL GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-05-14 | — | — | US | disclosed |
| EP-4090660-B1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-31 | — | — | EP | disclosed |
| EP-3823970-B1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-03 | — | — | EP | disclosed |
| CN-112771046-B | Other substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-12-15 | — | — | US | disclosed |
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-12-15 | — | — | US | disclosed |
| EP-4090660-A1 | QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2022-11-23 | — | — | EP | disclosed |
| WO-2021144439-A1 | QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021144439-A1 | QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-07-22 | — | — | WO | disclosed |
| US-20210163491-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-06-03 | — | — | US | disclosed |
| US-20210163491-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-06-03 | — | — | US | disclosed |
| EP-3823970-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-05-26 | — | — | EP | disclosed |
| CN-112771046-A | Other substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-10981918-B2 | Further substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2021-04-20 | — | — | US | disclosed |
| US-10981918-B2 | Further substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2021-04-20 | — | — | US | disclosed |
| WO-2020016452-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016452-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163491-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | NR3C1, GRK5, NR3C2 | MOGAT2 3729/4885AKR1B1 142/4885NR3C1 1/4885 |
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | MOGAT2 3478/4885AKR1B1 195/4885NR3C1 1/4885 |
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | NR3C1, GRK5, NR3C2 | MOGAT2 3729/4885AKR1B1 142/4885NR3C1 1/4885 |
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | NR3C1, GRK5, NR3C2 | MOGAT2 3729/4885AKR1B1 142/4885NR3C1 1/4885 |
| US-10981918-B2 | Further substituted triazolo quinoxaline derivatives | NR3C1, GRK5, NR3C2 | MOGAT2 3729/4885AKR1B1 142/4885NR3C1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.